Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro
Abstract
The atypical antipsychotic olanzapine has relatively high affinity for a number of neuronal receptors in radioreceptor binding assays. The ability of olanzapine to activate or antagonize a number of neuronal receptors was investigated in vitro, in cell lines transfected selectively with receptor subtypes and in receptor-selective isolated tissue studies. Olanzapine had no agonist activity at any of the receptors examined. However, olanzapine was a potent antagonist of 5-HT-stimulated increases in IP3 in cell lines transfected with 5-HT2A or 5-HT2B receptors with IC50 values of 30-40 nM. Olanzapine weakly blocked 5-HT-induced formation of IP3 in cell lines transfected with 5-HT2c receptors, but in this cell line potently inhibited 5-HT-stimulated [35S]GTP gamma S binding with a Ki value of 15 nM. Olanzapine blocked dopamine-stimulated adenylyl cyclase in rat retina with modest potency (Ki = 69 nM), consistent with its relatively low affinity for dopamine D1 receptors. Olanzapine blocked agonist-induced activities at the muscarinic receptor subtypes M1, M2, M3, and M5 with Ki values of 70, 622, 126, and 82 nM, respectively. In studies using cell lines transfected with muscarinic M4 receptors, olanzapine and the atypical antipsychotic clozapine did not have agonist activities as determined with cAMP inhibition and stimulation assays, arachidonic acid release and [35S]GTP gamma S binding assays. However, olanzapine antagonized agonist-induced effects in muscarinic M4 cells with a Ki value of 350 nM. In isolated tissue studies, olanzapine potently blocked agonist-induced effects at alpha 1-adrenergic and histamine H1 receptors (KB = 9 and 19 nM, respectively). Thus, olanzapine was an antagonist at all receptors investigated and was a particularly potent antagonist at 5-HT2A, 5-HT2B, 5-HT2C, alpha 1-adrenergic and histamine H1 receptors. Olanzapine was a weaker antagonist at muscarinic and dopamine D1 receptors.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The pronounced sedation for olanzapine oral and LAI may be due to their strong binding to histamine receptors (Bymaster et al., 1999).
“probably due to their strong binding to histamine receptors(Bymaster et al., 1999)”
From Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis (2024) · cites this paper as Bymaster et al., 1999
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922 · see citing works
DeLÉAN, A., Munson, P. J., & Rodbard, D. (1978) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1978.235.2.e97 · Cited by 2,384 · see citing works
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,352 · see citing works
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Gompel, P. V., Lesage, A. S., Loore, K. D., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167 · see citing works
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P. M., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,061 · see citing works
Self-citationOpposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum
Stoof, J. C., & Kebabian, J. W. (1981) · Nature · doi:10.1038/294366a0 · Cited by 920 · see citing works
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G. D., Tran, P., SATTERLEE, W. G., Sanger, T. M., & Hamilton, S. H. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 777 · see citing works
Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715 · see citing works
Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes
Peralta, E. G., Ashkenazi, A., Winslow, J. W., Ramachandran, J., & Capon, D. J. (1988) · Nature · doi:10.1038/334434a0 · Cited by 658 · see citing works
Sawaguchi, T., & Goldman‐Rakic, P. S. (1994) · Journal of Neurophysiology · doi:10.1152/jn.1994.71.2.515 · Cited by 649 · see citing works
Antagonist binding profiles of five cloned human muscarinic receptor subtypes.
Dörje, F., Wess, J., Lambrecht, G., Tacke, R., Mutschler, E., & Brann, M. R. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23208-6 · Cited by 611 · see citing works
Choudhary, M. S., Craigo, S. C., Sibley, D. R., Roth, B. L., Monsma, F. J., Shen, Y., Uluer, A., & Meltzer, H. Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/74zp-ze10 · Cited by 592 · see citing works
Sim, L. J., Selley, D. E., & Childers, S. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7242 · Cited by 455 · see citing works
Levey, A. I. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90300-r · Cited by 452 · see citing works
The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.
Moore, N., Tye, N. C., Axton, M., & Risius, F. C. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10792-1 · Cited by 277 · see citing works
Depressive Signs and Symptoms in Schizophrenia
Tollefson, G. D., Sanger, T. M., Lu, Y., & Thieme, M. E. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.3.250 · Cited by 259 · see citing works
Antipsychotic agents antagonize non-competitiveN-methyl-d-aspartate antagonist-induced behaviors
Corbett, R., Camacho, F., Woods, A. T., Kerman, L. L., Fishkin, R. J., Brooks, K., & Dunn, R. W. (1995) · Psychopharmacology · doi:10.1007/bf02246146 · Cited by 248 · see citing works
Zetterström, T., Sharp, T., & Ungerstedt, U. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90674-5 · Cited by 246 · see citing works
Clozapine is a potent and selective muscarinic M4 receptor agonist
Zorn, S. H., Jones, S. B., Ward, K. M., & Liston, D. R. (1994) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(94)90047-7 · Cited by 190 · see citing works
Li, X., Perry, K. W., Wong, D. T., & Bymaster, F. P. (1998) · Psychopharmacology · doi:10.1007/s002130050551 · Cited by 189 · see citing works
Self-citationHippius, H. (1989) · Psychopharmacology · doi:10.1007/bf00442551 · Cited by 171 · see citing works
In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
Bymaster, F. P., Rasmussen, K. G., Calligaro, D. O., NELSON, D. A., DeLapp, N. W., Wong, D. T., & Moore, N. A. (1997) · PubMed · Cited by 162 · see citing works
Self-citationInfluence of noncholinergic drugs on rat striatal acetylcholine levels
McGeer, P. L., Grewaal, D. S., & McGeer, E. G. (1974) · Brain Research · doi:10.1016/0006-8993(74)90685-4 · Cited by 160 · see citing works
Lazareno, S., & Birdsall, N. J. M. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13738.x · Cited by 156 · see citing works
Svensson, T. H., Mathé, J. M., ANDERSSON, J. L., NOMIKOS, B. G., Hildebrand, B. E., & Marcus, M. M. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00003 · Cited by 153 · see citing works
Meek, J. L., & Neff, N. H. (1973) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29446-0 · Cited by 139 · see citing works
The Genetics of Personality Disorder
McGuffin, P., & Thapar, A. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.160.1.12 · Cited by 139 · see citing works
Do Central Antiadrenergic Actions Contribute to the Atypical Properties of Clozapine?
Baldessarini, R. J., Huston-Lyons, D., Campbell, A., Marsh, E. R., & Cohen, B. M. (1992) · The British Journal of Psychiatry · doi:10.1192/s0007125000296852 · Cited by 134 · see citing works
Bymaster, F. P., Hemrick-Luecke, S. K., Perry, K. W., & Fuller, R. W. (1996) · Psychopharmacology · doi:10.1007/bf02245608 · Cited by 133 · see citing works
Self-citationA-61603, a potent alpha 1-adrenergic receptor agonist, selective for the alpha 1A receptor subtype.
Knepper, S. M., Buckner, S. A., Brune, M. E., DeBernardis, J. F., Meyer, M. D., & Hancock, A. A. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10708-8 · Cited by 132 · see citing works
Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.
Wainscott, D. B., Cohen, M. L., Schenck, K. W., Audia, J. E., Nissen, J. S., Baez, M., Kursar, J. D., Lucaites, V. L., & Nelson, D. L. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13628-6 · Cited by 122 · see citing works
Wainscott, D. B., Lucaites, V. L., Kursar, J. D., Baez, M., & Nelson, D. L. G. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12346-x · Cited by 118 · see citing works
The Effect of Clozapine on Plasma Norepinephrine: Relationship to Clinical Efficacy
Breier, A. F., Buchanan, R. W., Waltrip, R. W., Listwak, S. J., Holmes, C. S., & Goldstein, D. S. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.1 · Cited by 115 · see citing works
Evidence that M3 muscarinic receptors in rat parotid gland couple to two second messenger systems
Dai, Y. S., Ambudkar, I. S., Horn, V., Yeh, C., Kousvelari, E. E., Wall, S. J., Li, M., Yasuda, R. P., Wolfe, B. B., & Baum, B. J. (1991) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1991.261.6.c1063 · Cited by 114 · see citing works
Some atypical neuroleptics inhibit [3H]SCH 23390 binding in vivo
Andersen, P. H., Nielsen, E. B., Grønvald, F. C., & Bræstrup, C. (1986) · European Journal of Pharmacology · doi:10.1016/0014-2999(86)90656-4 · Cited by 97 · see citing works
Functional responses of cloned muscarinic receptors expressed in CHO-K1 cells.
Jones, S. V. P., Heilman, C. J., & Brann, M. R. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)12921-0 · Cited by 96 · see citing works
Muscarinic m4 receptor activation by some atypical antipsychotic drugs
Zeng, X. P., Le, F., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00956-9 · Cited by 93 · see citing works
Felder, C. C., Williams, H. L., & Axelrod, J. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6477 · Cited by 90 · see citing works
Effects of drugs on regional brain concentrations of dopamine and dihydroxyphenylacetic acid.
Umezu, K., & Moore, K. E. (1979) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31522-3 · Cited by 87 · see citing works
Stanton, T., Watson, C. B., Cusack, B. M., & Richelson, E. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90211-e · Cited by 84 · see citing works
Brain region effects of clozapine on amino acid and monoamine transmission.
Yamamoto, B. K., Pehek, E. A., & Meltzer, H. Y. (1994) · PubMed · Cited by 80 · see citing works
Rasmussen, K. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90001-2 · Cited by 76 · see citing works
Receptor subtype and density determine the coupling repertoire of the 5-ht2 receptor subfamily
Lucaites, V. L., Nelson, D. L. G., Wainscott, D. B., & Baez, M. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00423-7 · Cited by 67 · see citing works
Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists
Richards, M. H., & van Giersbergen, P. L. M. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb13339.x · Cited by 66 · see citing works
Thomas, D. R., Faruq, S. A., Balcarek, J. M., & Brown, A. M. (1995) · Journal of Receptors and Signal Transduction · doi:10.3109/10799899509045217 · Cited by 63 · see citing works
Felder, C. C., Dieter, P., Kinsella, J., Tamura, K., Kanterman, R. Y., & Axelrod, J. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22970-6 · Cited by 58 · see citing works
Olianas, M. C., Maullu, C., & Onali, P. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701357 · Cited by 56 · see citing works
Fuller, R. W., & Snoddy, H. D. (1992) · PubMed · Cited by 49 · see citing works
Marshall, I., Burt, R. P., Green, G. M., Hussain, M. B., & Chapple, C. R. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb16001.x · Cited by 47 · see citing works
Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo
Hemrick-Luecke, S. K., Snoddy, H. D., & Fuller, R. W. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00739-x · Cited by 46 · see citing works
Przegaliński, E., Kordecka-Magiera, A., Mogilnicka, E. M., & Maj, J. (1981) · Psychopharmacology · doi:10.1007/bf00432691 · Cited by 36 · see citing works
Hollander, E., & Cohen, L. J. (1994) · PubMed · Cited by 35 · see citing works
Calligaro, D. O., Fairhurst, J., Hotten, T. M., Moore, N. A., & Tupper, D. E. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(96)00567-7 · Cited by 32 · see citing works
Riggs, R. M., Nichols, D. E., Foreman, M. M., Truex, L. L., Glock, D., & Kohli, J. D. (1987) · Journal of Medicinal Chemistry · doi:10.1021/jm00391a029 · Cited by 26 · see citing works
Moghaddam, B., & Bunney, B. S. (1990) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(90)90086-v · Cited by 25 · see citing works
Serotonin 5-HT2 Receptor Antagonists
Stefański, R., & Goldberg, S. R. (1997) · CNS Drugs · doi:10.2165/00023210-199707050-00006 · Cited by 23 · see citing works
Effect of prazosin on norepinephrine concentration and turnover in rat brain and heart.
Fuller, R. W., Snoddy, H. D., & Perry, K. W. (1978) · PubMed · Cited by 18 · see citing works
Deveney, A. M., & Waddington, J. L. (1996) · Psychopharmacology · doi:10.1007/bf02245604 · Cited by 18 · see citing works
Donaldson, J., & Hill, S. J. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb16848.x · Cited by 17 · see citing works
Baumgold, J., Dyer, K., Falcone, J. F., & Bymaster, F. P. (1995) · Cellular Signalling · doi:10.1016/0898-6568(94)00067-l · Cited by 13 · see citing works
Self-citationThe effect of olanzapine on cognition and psychomotor function in healthy elderly volunteers
Taylor, N. F., Beuzen, J. N., Wesnes, K. A., & Wood, A. J. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(96)85439-9 · Cited by 9 · see citing works
Bymaster, F. P., Li, X., Carter, P. A., Wong, D. T., & Perry, K. W. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)82201-3 · Cited by 2 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Street, J. S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.968 · Cited by 583 · see citing works
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336 · see citing works
Towards a muscarinic hypothesis of schizophrenia
Raedler, T., Bymaster, F., Tandon, R., Copolov, D., & Dean, B. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001924 · Cited by 289 · see citing works
Self-citationAntipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities
McIntyre, R. S., McCann, S., & Kennedy, S. H. (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674370104600308 · Cited by 261 · see citing works
Ichikawa, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00312-8 · Cited by 248 · see citing works
Crook, J. M., Tomaskovic‐Crook, E., Copolov, D., & Dean, B. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00918-5 · Cited by 228 · see citing works
Crook, J., Tomaskovic-Crook, E., Copolov, D., & Dean, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.918 · Cited by 224 · see citing works
Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 223 · see citing works
Self-citationBhana, N., Foster, R. H., Olney, R., & Plosker, G. L. (2001) · Drugs · doi:10.2165/00003495-200161010-00011 · Cited by 217 · see citing works
Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences
Aringhieri, S., Carli, M., Kolachalam, S., Verdesca, V., Cinì, E., Rossi, M., McCormick, P., Corsini, G., Maggio, R., & Scarselli, M. (2018) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2018.06.012 · Cited by 182 · see citing works
Konradi, C. L., & Heckers, S. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01267-7 · Cited by 200 · see citing works
Jordan, K., Gralla, R., Jahn, F., & Molassiotis, A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.073 · Cited by 196 · see citing works
Atypical Antipsychotic-Induced Weight Gain
Roerig, J. L., Steffen, K. J., & Mitchell, J. E. (2011) · CNS Drugs · doi:10.2165/11596300-000000000-00000 · Cited by 166 · see citing works
Kinon, B. J., Kaiser, C. J., Ahmed, S., Rotelli, M. D., & Kollack‐Walker, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000161501.65890.22 · Cited by 164 · see citing works
The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C
Lord, C. C., Wyler, S. C., Wan, R., Castorena, C. M., Ahmed, N. I., Mathew, D., Lee, S., Liu, C., & Elmquist, J. K. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93362 · Cited by 161 · see citing works
Atypical antipsychotics in bipolar depression: potential mechanisms of action.
Yatham, L. N., Goldstein, J. M., Vieta, E., Bowden, C. L., Grunze, H., Post, R. M., Suppes, T. M., & Calabrese, J. R. (2005) · PubMed · Cited by 159 · see citing works
Coccurello, R., & Moles, A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.008 · Cited by 146 · see citing works
Update and new trends in antiemetic therapy: the continuing need for novel therapies.
Feyer, P., & Jordan, K. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq600 · Cited by 145 · see citing works
Muscarinic mechanisms of antipsychotic atypicality
Bymaster, F. P., Felder, C. C., Tzavara, E. T., Nomikos, G. G., Calligaro, D. O., & McKinzie, D. L. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.008 · Cited by 140 · see citing works
Self-citationAn update of safety of clinically used atypical antipsychotics
Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., Iasevoli, F., Buonaguro, E. F., Fornaro, M., Fiengo, A. L. C., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1201475 · Cited by 135 · see citing works
CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.
Siuciak, J., Chapin, D., McCarthy, S. A., Guanowsky, V., Brown, J. A., Chiang, P., Marala, R., Patterson, T., Seymour, P., Swick, A., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.07.024 · Cited by 132 · see citing works
The Psychopharmacology of Aggressive Behavior
Comai, S., Tau, M., & Gobbi, G. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f8770 · Cited by 132 · see citing works
Sowell, M. O., Mukhopadhyay, N. D., Cavazzoni, P. A., Shankar, S. S., Steinberg, H. O., Breier, A. F., Beasley, C. M., & Dananberg, J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8599 · Cited by 129 · see citing works
Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine
Bymaster, F. P., Falcone, J. F., Bauzon, D., Kennedy, J. S., Schenck, K. W., DeLapp, N. W., & Cohen, M. L. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01399-1 · Cited by 122 · see citing works
Self-citationThe Psychopharmacology of Aggressive Behavior
Comai, S., Tau, M., Pavlovic, Z. M., & Gobbi, G. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31824929d6 · Cited by 120 · see citing works
An animal model of antipsychotic-induced weight gain
Arjona, A. A. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.09.040 · Cited by 118 · see citing works
The Role of Thermogenesis in Antipsychotic Drug‐induced Weight Gain
Stefanidis, A., Verty, A. N. A., Allen, A. M., Owens, N. C., Cowley, M. A., & Oldfield, B. J. (2008) · Obesity · doi:10.1038/oby.2008.468 · Cited by 104 · see citing works
Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats
Weston–Green, K., Huang, X., & Deng, C. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.10.039 · Cited by 104 · see citing works
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs
Bisson, W. H., Cheltsov, A. V., Bruey-Sédano, N., Lin, B., Chen, J., Goldberger, N. E., May, L. T., Christopoulos, A., Dalton, J. T., Sexton, P. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609752104 · Cited by 99 · see citing works
Alterations of Serotonin Transmission in Schizophrenia
Abi‐Dargham, A. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(06)78005-9 · Cited by 98 · see citing works
In Vivo DA D1 Receptor Selectivity of NNC 112 and SCH 23390
Ekelund, J., Slifstein, M., Narendran, R., Guillin, O., Belani, H., Guo, N., Hwang, Y., Hwang, D., Abi‐Dargham, A., & Laruelle, M. A. (2007) · Molecular Imaging and Biology · doi:10.1007/s11307-007-0077-4 · Cited by 94 · see citing works
Virtual Screen for Ligands of Orphan G Protein-Coupled Receptors
Bock, J. R., & Gough, D. A. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci050006d · Cited by 96 · see citing works
Central Nervous System Delivery of the Antipsychotic Olanzapine Induces Hepatic Insulin Resistance
Martins, P. J. F., Haas, M., & Obici, S. (2010) · Diabetes · doi:10.2337/db10-0449 · Cited by 91 · see citing works
In Vivo Olanzapine Occupancy of Muscarinic Acetylcholine Receptors in Patients with Schizophrenia
Raedler, T. J. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00162-1 · Cited by 82 · see citing works
Poyurovsky, M., Fuchs, C., Pashinian, A., Levi, A., Faragian, S., Maayan, R., & Gil‐Ad, I. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0731-1 · Cited by 80 · see citing works
Jutila, A., Söderlund, T., Pakkanen, A. L., HUTTUNEN, M. O., & Kinnunen, P. K. J. (2001) · Chemistry and Physics of Lipids · doi:10.1016/s0009-3084(01)00175-x · Cited by 80 · see citing works
Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine
Mann, K., Rossbach, W., Müller, M. J., Müller-Siecheneder, F., Pott, T., Linde, I., Dittmann, R. W., & Hiemke, C. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.08.005 · Cited by 78 · see citing works
Bymaster, F. P., & Felder, C. C. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001019 · Cited by 76 · see citing works
Self-citationYanai, T., Iwasa, S., Hashimoto, H., Ohyanagi, F., Takiguchi, T., Takeda, K., Nakao, M., Sakai, H., Nakayama, T., Minato, K., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1200-4 · Cited by 74 · see citing works
An open pilot trial of olanzapine for delirium in the Korean population
Kim, K., Pae, C., Chae, J., Bahk, W., & Jun, T. (2001) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2001.00898.x · Cited by 75 · see citing works
Poyurovsky, M., Fuchs, C., Pashinian, A., Levi, A., Weizman, R., & Weizman, A. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2935-2 · Cited by 74 · see citing works
de Bartolomeis, A., Barone, A., Begni, V., & Riva, M. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106078 · Cited by 62 · see citing works
Minet-Ringuet, J., Even, P., Goubern, M., Tomé, D., & de Beaurepaire, R. (2006) · Appetite · doi:10.1016/j.appet.2006.01.008 · Cited by 74 · see citing works
Olanzapine in the Treatment of Developmental Stuttering: A Double-Blind, Placebo-Controlled Trial
Maguire, G. A., Riley, G. D., Franklin, D. L., Maguire, M. E., Nguyen, C. T., & Brojeni, P. H. (2004) · Annals of Clinical Psychiatry · doi:10.1080/10401230490452834 · Cited by 69 · see citing works
Davoodi, N., Kalinichev, M., Korneev, S. A., & Clifton, P. G. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1415-1 · Cited by 67 · see citing works
Carli, M., Calcagno, E., Mainolfi, P., Mainini, E., & Invernizzi, R. W. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2065-7 · Cited by 64 · see citing works
Comparison of Olanzapine to Risperidone in Substance‐Abusing Individuals with Schizophrenia
Akerele, E., & LEVIN, F. R. (2007) · American Journal on Addictions · doi:10.1080/10550490701389658 · Cited by 63 · see citing works
Bhana, N., & Perry, C. M. (2001) · CNS Drugs · doi:10.2165/00023210-200115110-00005 · Cited by 61 · see citing works
Chemogenomics in Drug Discovery
Kubinyi, H. (2007) · Springer eBooks · doi:10.1007/978-3-540-37635-4_1 · Cited by 62 · see citing works
Bortolozzi, A. A., Amargós‐Bosch, M., Adell, A., Díaz-Mataix, L., Serrats, J., Pons, S., & Artigas, F. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02829.x · Cited by 62 · see citing works
Dose Response and Atypical Antipsychotics in Schizophrenia
Kinon, B. J., AHL, J. S. B., Stauffer, V. L., Hill, A. L., & Buckley, P. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418090-00005 · Cited by 59 · see citing works
Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder
Keshavan, M. S. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.12.008 · Cited by 57 · see citing works
Brea, J. M., Rodrigo, J., Carrieri, A., Sanz, F., Cadavid, M. I., Enguix, M. J., Villazón, M., Mengod, G., Caro, Y., Masaguer, C. F., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm011014y · Cited by 56 · see citing works
The Benefits of Olanzapine in Palliating Symptoms
Davis, M. P., & Sanger, G. J. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00804-1 · Cited by 54 · see citing works
Effect of a single-dose of olanzapine on sleep in healthy females and males
Lindberg, N., Virkkunen, M., Tani, P., Appelberg, B., Virkkala, J., n, R. R., & Porkka‐Heiskanen, T. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200207000-00004 · Cited by 54 · see citing works
Teaktong, T., Piggott, M. A., McKeith, I. G., Perry, R. H., Ballard, C. G., & Perry, E. K. (2005) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.02.019 · Cited by 53 · see citing works
Receptor targets for antidepressant therapy in bipolar disorder: An overview
Fountoulakis, K. Ν., Kelsoe, J. R., & Akiskal, H. S. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.04.043 · Cited by 52 · see citing works
Perry, K. W., Nisenbaum, L. K., George, C. A., Shannon, H. E., Felder, C. C., & Bymaster, F. P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01017-9 · Cited by 52 · see citing works
Self-citationActivity-based anorexia animal model: a review of the main neurobiological findings
Spadini, S., Ferro, M., Lamanna, J., & Malgaroli, A. (2021) · Journal of Eating Disorders · doi:10.1186/s40337-021-00481-x · Cited by 54 · see citing works
Serotonergic approaches in the development of novel antipsychotics
Jones, C. A., & McCreary, A. C. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.025 · Cited by 50 · see citing works
Dalton, G. L., Lee, M. D., Kennett, G. A., Dourish, C. T., & Clifton, P. G. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.11.012 · Cited by 50 · see citing works
Didriksen, M., Kreilgaard, M., & Arnt, J. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.05.021 · Cited by 50 · see citing works
Ichikawa, J., Dai, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02544-1 · Cited by 49 · see citing works
Upright, N. A., & Baxter, M. G. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0660-9 · Cited by 47 · see citing works
Jin, C. Y., & Panula, P. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.12.017 · Cited by 47 · see citing works
Cognitive effects of olanzapine treatment in schizophrenia.
McGurk, S. R., Lee, M. A., Jayathilake, K., & Meltzer, H. Y. (2004) · PubMed Central · Cited by 47 · see citing works
Coccurello, R., Caprioli, A., Ghirardi, O., Conti, R., Ciani, B., Daniele, S., Bartolomucci, A., & Moles, A. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0368-5 · Cited by 46 · see citing works
Torta, R., & Monaco, F. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.043s2008.x · Cited by 45 · see citing works
Coccurello, R., Brina, D., Caprioli, A., Conti, R., Ghirardi, O., Schepis, F., & Moles, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181bfe13e · Cited by 44 · see citing works
Bymaster, F. P., & Falcone, J. F. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00037-6 · Cited by 44 · see citing works
Self-citationWang, D., Schneider-Thoma, J., Siafis, S., Qin, M., Wu, H., Zhu, Y., Davis, J. M., Priller, J., & Leucht, S. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.03.003 · Cited by 44 · see citing works
Wiśniewska, A., & Wolnicka-Głubisz, A. (2004) · Biophysical Chemistry · doi:10.1016/j.bpc.2004.04.001 · Cited by 42 · see citing works
van der Zwaal, E. M., Merkestein, M., Lam, Y. K., Brans, M. A. D., Luijendijk, M. C. M., Bok, L. I. H., Verheij, E. R., la Fleur, S. E., & Adan, R. A. H. (2011) · International Journal of Obesity · doi:10.1038/ijo.2011.97 · Cited by 39 · see citing works
Rodygin, K. S., Bogachenkov, A. S., & Ananikov, V. P. (2018) · Molecules · doi:10.3390/molecules23030648 · Cited by 39 · see citing works
Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents
Calarge, C. A., Ivins, S. D., Motyl, K. J., Shibli-Rahhal, A. A., Bliziotes, M. M., & Schlechte, J. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125313487548 · Cited by 39 · see citing works
Sato, H., Ito, C., Hiraoka, K., Tashiro, M., Shibuya, K., Funaki, Y., Yoshikawa, T., Iwata, R., Matsuoka, H., & Yanai, K. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4002-2 · Cited by 39 · see citing works
Freedenfeld, R. N., Murray, M., Fuchs, P. N., & Kiser, R. S. (2006) · Pain Practice · doi:10.1111/j.1533-2500.2006.00072.x · Cited by 38 · see citing works
Deng, C., Weston–Green, K., Han, M., & Huang, X. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.02.009 · Cited by 35 · see citing works
Antipsychotics as antidepressants
Roberts, R. J., Lohano, K., & El‐Mallakh, R. S. (2015) · Asia-Pacific Psychiatry · doi:10.1111/appy.12186 · Cited by 34 · see citing works
Bai, Y. M., Chen, T., Liou, Y., Hong, C., & Tsai, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.030 · Cited by 34 · see citing works
Effects of chronic typical and atypical antipsychotic drug treatment on maternal behavior in rats
Li, M., Budin, R., Fleming, A. S., & Kapur, S. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.012 · Cited by 34 · see citing works
Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine
Rico‐Villademoros, F., Hidalgo, J. L. L., Dominguez, I., Garcia‐Leiva, J. M., & Calandre, E. P. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.08.012 · Cited by 33 · see citing works
Liu, C., Lee, S., & Elmquist, J. K. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.02.008 · Cited by 32 · see citing works
Treatment of Intractable Hiccups With Olanzapine Following Recent Severe Traumatic Brain Injury
Alderfer, B. S., & Arciniegas, D. B. (2006) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.18.4.551 · Cited by 32 · see citing works
Cognitive impairment in elderly patients with schizophrenia: age related changes
Harvey, P. D. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200112)16:1+ · Cited by 44 · see citing works
Self-citationAntipsychotics as antidepressants: what is the mechanism?
Šagud, M., Mihaljević-Peleš, A., Begić, D., Vuksan‐Ćusa, B., Kramarić, M., Živković, M., & Jakovljević, M. (2011) · PubMed · Cited by 29 · see citing works
Raedler, T. J. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006584 · Cited by 29 · see citing works
Evers, S. S., Calcagnoli, F., van Dijk, G., & Scheurink, A. J. W. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.05.029 · Cited by 28 · see citing works
From ultimatum to Nash bargaining: Theory and experimental evidence
Fischer, S., Güth, W., Müller, W., & Stiehler, A. (2006) · Experimental Economics · doi:10.1007/s10683-006-1468-0 · Cited by 28 · see citing works
Muscarinic mechanisms in psychotic disorders.
McKinzie, D., & Bymaster, F. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_9 · Cited by 22 · see citing works
Self-citationVanover, K. E., Harvey, S. C., Son, T., Bradley, S. R., Kold, H., Makhay, M. M., Veinbergs, I., Spalding, T. A., Weiner, D. M., Andersson, C., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.066688 · Cited by 27 · see citing works
Oruch, R., Lund, A., Pryme, I. F., & Holmsen, H. (2010) · Journal of Chemical Biology · doi:10.1007/s12154-009-0034-6 · Cited by 26 · see citing works
Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
Gyawali, B., Poudyal, B. S., & Iddawela, M. Y. (2016) · Journal of Global Oncology · doi:10.1200/jgo.2015.002477 · Cited by 26 · see citing works
Complexity, Bounded Rationality and Heuristic Search
MacLeod, W. B. (2001) · Contributions in Economic Analysis & Policy · doi:10.2202/1538-0645.1059 · Cited by 26 · see citing works
Nallapati, S. B., Sreenivas, B. Y., Bankala, R., Parsa, K. V. L., Shivashankar, S., Mukkanti, K., & Pal, M. (2015) · RSC Advances · doi:10.1039/c5ra20380e · Cited by 25 · see citing works
Choy, K. H. C., Shackleford, D. M., Malone, D. T., Mistry, S. N., Patil, R. T., Scammells, P. J., Langmead, C. J., Pantelis, C., Sexton, P. M., Lane, J. R., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235788 · Cited by 25 · see citing works
Asaoka, N., Nagayasu, K., Nishitani, N., Yamashiro, M., Shirakawa, H., Nakagawa, T., & Kaneko, S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.032 · Cited by 24 · see citing works
123I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M1In Vivo
Bakker, G., Vingerhoets, W. A. M., van Wieringen, J., de Bruin, K. M., Eersels, J. L. H., de Jong, J., Chahid, Y., Rutten, B. P. F., DuBois, S. L., Watson, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147488 · Cited by 24 · see citing works
Zhao, C., & Li, M. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.08.021 · Cited by 24 · see citing works
Optimization of a mathematical topological pattern for the prediction of antihistaminic activity
Duart, M. J., García‐Domenech, R., Antón-Fos, G. M., & Gálvez, J. (2001) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1011115824070 · Cited by 23 · see citing works
- Authors
- Bymaster, F.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Bymaster, F
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 1999-05-04
- Volume
- 37
- Issue
- 1
- Pages
- 107-122
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2113107587
- Cited by
- 200
- References
- 62
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 2 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 8 · 2015: 10 · 2014: 5 · 2013: 5 · 2012: 10
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Schizophrenia Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- olanzapine, atypical antipsychotics
- MeSH terms
- Olanzapine, Adenylyl Cyclases, Animals, Benzodiazepines, Cells, Cultured, Cricetinae, Kinetics, Pirenzepine, Receptors, Adrenergic, alpha, Receptors, Histamine H1, Receptors, Muscarinic, Receptors, Serotonin, Retina, Receptors, Dopamine D1, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
